MedTrace Logo

Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)

NCT02354261 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2020-08-05

No results posted yet for this study

Summary

The study will assess the safety and efficacy of SUBA-Cap in subjects with Basal Cell Carcinoma Nevus Syndrome.

Conditions

  • Basal Cell Carcinoma in Basal Cell Nevus Syndrome

Interventions

DRUG

SUBA-Itraconazole

Subjects will receive an oral dose of 300 mg SUBA-Itraconazole daily.

Sponsors & Collaborators

  • HedgePath Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • James Solomon, MD, PhD · Ameriderm Clinical Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-07
Primary Completion
2019-03-31
Completion
2019-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02354261 on ClinicalTrials.gov